AMES, Iowa, March 21 /PRNewswire-FirstCall/ -- BioForce Nanosciences Holdings, Inc. (“BioForce”), , today announced that it has closed a $6 million Private Placement of restricted common shares @$1.50/share. The company’s shares trade under the symbol BFNH.
Dr. Eric Henderson, BioForce founder and CEO and an early developer of nanotechnology tools, said, “With this financing, and the recent addition of key senior management, BioForce is well positioned to take full advantage of the commercial opportunities that our NanoArrayer(TM) System provides. This funding will also facilitate continued development of the company’s pipeline technologies.”
BioForce’s core technology, the NanoArrayer(TM) System, is a proprietary instrumentation and software tool that is poised to impact multiple areas in the life sciences. The NanoArrayer(TM) is a new and enabling platform for addressing previously intractable research problems, thereby enhancing the opportunity for scientific breakthroughs.
The company is also commercializing a patented diagnostic device called the ViriChip(TM) System, which is used for detection and identification of multiple viruses and other pathogens simultaneously on a single chip. The ViriChip(TM) is a consumable product that creates a recurring revenue opportunity.
About BioForce Nanosciences Holdings, Inc.
BioForce creates products that enable future advances in nanotechnology across a broad spectrum of industries. The company has developed, patented and initiated commercialization of a unique instrument called the NanoArrayer(TM). The NanoArrayer(TM) is a tabletop device with the ability to print and pattern thousands of molecular domains on a chip in an extremely miniaturized format. Another emphasis of the company is the patented ViriChip(TM) System for the direct, non-destructive and simultaneous detection and identification of multiple viruses. BioForce is synergistically expanding its technology foundation with a pipeline of additional tools and devices through both internal and external growth. The company’s founder and CEO, Dr. Eric Henderson, is a pioneer in the application of nanotechnology to life sciences research and development.
This news release may contain certain forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are based on current expectations and the current economic environment. Readers are cautioned not to put undue reliance on such forward-looking statements. Unknown risks and uncertainties, including those described in the company’s most recent filings with the Securities and Exchange Commission, may cause actual results to differ materially from those contained in forward-looking statements. The forward-looking statements are made only as of the date of this news release and the company assumes no duty to publicly update these statements to reflect subsequent events or circumstances.
BioForce Nanosciences Holdings, Inc.
CONTACT: Jaime Naig of Hanser & Associates (for BioForce Nanosciences)+1-515-224-1086, jaime@hanser.com
